# EDGAR Filing Document

**Accession Number:** 0002048828
**File Stem:** 0001641172-25-024711
**Filing Date:** 2025-8
**Character Count:** 11424
**Document Hash:** abe773cdf58671859fb37888bc2a1d4c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-024711.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001641172-25-024711

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OS Therapies Inc
- **CENTRAL INDEX KEY:** 0001795091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825118368
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94604
- **FILM NUMBER:** 251229533

**BUSINESS ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 410-297-7793

**MAIL ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OS THERAPIES Inc
- **DATE OF NAME CHANGE:** 20191125
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Auerbach Shalom
- **CENTRAL INDEX KEY:** 0002048828

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 15 ATLANTIC AVENUE
- **STREET 2:** SUITE M2
- **CITY:** LYNBROOK
- **STATE:** NY
- **ZIP:** 11563

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**OS Therapies Inc**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**68764Y207**

*(CUSIP Number)*

**Shalom Auerbach**<br>15 Atlantic Avenue,<br>Suite M2<br>Lynbrook NY 11563<br>917-364-7051

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/29/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **68764Y207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Shalom Auerbach** | Name of reporting person<br>**Shalom Auerbach** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2677570.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2677570.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2677570.00** | Aggregate amount beneficially owned by each reporting person<br>**2677570.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.5%** | Percent of class represented by amount in Row (11)<br>**8.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

| **CUSIP No.** | **68764Y207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Einodmil LLC** | Name of reporting person<br>**Einodmil LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2654199.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2654199.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2654199.00** | Aggregate amount beneficially owned by each reporting person<br>**2654199.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.4%** | Percent of class represented by amount in Row (11)<br>**8.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
OS Therapies Inc

**(c) Address of Issuer's Principal Executive Offices:**
115 Pullman Crossing Road, Suite #103, Grasonville, MD, 21638

Item 1 of the Schedule 13D is hereby supplemented as follows: This Amendment No. 4 (this "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons (as defined in Item 2 of the Schedule 13D) with the SEC (as defined in Item 5 of the Schedule 13D) on January 17, 2025 (the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported on the Schedule 13D or the Schedule 13D/A filed by the Reporting Persons with the SEC on February 28, 2025 ("Amendment No. 1"), March 12, 2025 ("Amendment No. 2") and May 9, 2025 ("Amendment No. 3"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D, Amendment No 1, Amendment No. 2 and Amendment No. 3, as applicable. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment is hereby incorporated by reference in its entirety into this Item 5.

As of the date hereof, Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has sole voting and dispositive power. The holdings of Mr. Auerbach represent an aggregate of approximately 8.5% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

As of the date hereof, Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has sole voting and dispositive power. The holdings of Einodmil represent an aggregate of approximately 8.4% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

As of July 29, 2025, Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has sole voting and dispositive power. The holdings of Mr. Auerbach represent an aggregate of approximately 8.5% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

As of July 29, 2025, Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has sole voting and dispositive power. The holdings of Einodmil represent an aggregate of approximately 8.4% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

**(b)**
As of the date hereof, (i) Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has the sole voting and dispositive power, and (ii) Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has the sole voting and dispositive power.

As of July 29, 2025, (i) Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has the sole voting and dispositive power, and (ii) Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has the sole voting and dispositive power.

**(c)**
Except for the July 3, 2025 Sales, there were no other transactions by the Reporting Persons in shares of Common Stock as of the date hereof or during the period commencing sixty (60) days prior to the date hereof.

Except for the July 3, 2025 Sales, there were no other transactions by the Reporting Persons in shares of Common Stock as of July 29, 2025 or during the period commencing sixty (60) days prior to July 29, 2025.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Shalom Auerbach

**Signature:** /s/ Shalom Auerbach

**Name/Title:** Shalom Auerbach

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Einodmil LLC

**Signature:** /s/ Shalom Auerbach

**Name/Title:** Shalom Auerbach/Principal

**Date:** 08/18/2025